CD147 as a novel biomarker for predicting the prognosis and clinicopathological features of bladder cancer: a meta-analysis
Metrics: HTML 918 views | ?
Hongru Li1,*, Yadong Xu1,* and Hui Li2,*
1Xiangya Hospital, Central South University, Changsha, Hunan Province, China
2Reproductive Department, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
*These authors have contributed equally to this work
Keywords: bladder cancer, CD147, prognosis, clinicopathological features, meta-analysis
Received: November 14, 2016 Accepted: April 19, 2017 Published: July 15, 2017
Objective To assess the prognostic and clinicopathological characteristics of CD147 in human bladder cancer.
Methods Studies on CD147 expression in bladder cancer were retrieved from PubMed, EMBASE, the Cochrane Library, Web of Science, China National Knowledge Infrastructure, and the WanFang databases. Outcomes were pooled with meta-analyzing softwares RevMan 5.3 and STATA 14.0.
Results Twenty-four studies with 25 datasets demonstrated that CD147 expression was higher in bladder cancer than in non-cancer tissues (OR=43.64, P<0.00001). Moreover, this increase was associated with more advanced clinical stages (OR=73.89, P<0.0001), deeper invasion (OR=3.22, P<0.00001), lower histological differentiation (OR=4.54, P=0.0005), poorer overall survival (univariate analysis, HR=2.63, P<0.00001; multivariate analysis, HR=1.86, P=0.00036), disease specific survival (univariate analysis, HR=1.65, P=0.002), disease recurrence-free survival (univariate analysis, HR=2.78, P=0.001; multivariate analysis, HR=5.51, P=0.017), rate of recurrence (OR=1.91, P=0.0006), invasive depth (pT2~T4 vs. pTa~T1; OR=3.22, P<0.00001), and histological differentiation (low versus moderate-to-high; OR=4.54, P=0.0005). No difference was found among disease specific survival in multivariate analysis (P=0.067), lymph node metastasis (P=0.12), and sex (P=0.15).
Conclusion CD147 could be a biomarker for early diagnosis, treatment, and prognosis of bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.